AstraZeneca announced positive results from its BaxHTN phase III trial where baxdrostat, an aldosterone synthase inhibitor, achieved primary and secondary endpoints in patients with uncontrolled or treatment-resistant hypertension. The drug was acquired through AstraZeneca’s $1.8 billion purchase of CinCor Pharma and remains competitive with similar candidates approaching NDA submission.